BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Merck Sharp & Dohme Ltd. submitted on 30 October 2002 an application for Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
EMEND,  through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  25  July  2002,  this 
medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 
of 22 July 1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: 
Dr Per Nilsson 
Co-Rapporteur: Dr Barbara van Zwieten-Boot 
Scientific Advice: 
The applicant did not seek scientific advice from the CPMP. 
Licensing status: 
The product was authorised in the USA on 26 March 2003. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 18 November 2002. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on 
28 January 2003 (Annex 1). The Co-Rapporteur's first Assessment Report was circulated to all 
CPMP members on 3 February 2003 (Annex 2). 
During  the  meeting  on  18-19  March  2003  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 19 March 2003 (Annex 3). 
The  Applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 
14 April 2003. 
The  Rapporteur  and  Co-Rapporteur  circulated  the  response  Assessment  Report  on  the 
Applicant’s  responses  to  the  List  of  Questions  to  all  CPMP  members  on  26  May  2003 
(Annex 4). 
During the meeting on 24-26 June 2003, the CPMP adopted a list of outstanding issues sent to 
the Applicant on 26 June 2003 (Annex 5). 
The  company submitted the responses to the CPMP  consolidated list of outstanding  issues  on 
4 July 2003. 
The  Rapporteur  and  Co-Rapporteur  circulated  the  Assessment  Report  on  the  Applicant’s 
responses to the List of Outstanding Issues to all CPMP members on 15 July 2003 (Annex 6). 
During  the  meeting  on  22-24  July  2003,  outstanding  issues  were  addressed  by  the  Applicant 
who gave oral explanations before the CPMP on 23 July 2003. 
During the meeting on 22-24 July 2003 the CPMP, in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to EMEND on 24 July 2003. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 12 November 2003. 
1/1 
EMEA 2004 
 
 
